BACKGROUND: Endoscopic ultrasound guided fine needle aspiration biopsy (EUS-FNA) has proven to be an effective diagnostic modality for the detection and staging of pancreatic malignancies. In recent years EUS-FNA has also been used to diagnose lesions of non-pancreatic sites such as structures in close proximity to the gut wall within the mediastinum, abdomen, pelvis and retro-peritoneum. AIMS: To evaluate experience with EUS-FNA of non-pancreatic sites at a large university medical centre. METHODS: The study cohort included 234 patients who underwent EUS-FNA of 246 lesions in non-pancreatic sites (122 peri-pancreatic and coeliac lymph nodes; 9 peri-pancreatic masses; other sites: mediastinum 12, gastric 25, liver 27, oesophagus 17, duodenum/colon/rectum 15, retro-peritoneum 8, lung 7, miscellaneous 4). RESULTS: The cytology diagnoses were classified as non-neoplastic/reactive in 82 (33%), atypical/suspicious for malignancy in 25 (10%), malignant in 86 (35%) and non-diagnostic in 53 (22%) cases. Surgical pathology follow-up was available in 75 (31%) cases. Excluding the non-diagnostic cases there were 7 false negative and 3 false positive cases. The sensitivity, specificity and positive predictive value of EUS-FNA in the diagnosis of lesions of non-pancreatic sites was 92%, 98% and 97%, respectively. CONCLUSIONS: EUS-FNA can be effectively used as a diagnostic modality in the diagnosis of lesions from non-pancreatic sites.
BACKGROUND: Endoscopic ultrasound guided fine needle aspiration biopsy (EUS-FNA) has proven to be an effective diagnostic modality for the detection and staging of pancreatic malignancies. In recent years EUS-FNA has also been used to diagnose lesions of non-pancreatic sites such as structures in close proximity to the gut wall within the mediastinum, abdomen, pelvis and retro-peritoneum. AIMS: To evaluate experience with EUS-FNA of non-pancreatic sites at a large university medical centre. METHODS: The study cohort included 234 patients who underwent EUS-FNA of 246 lesions in non-pancreatic sites (122 peri-pancreatic and coeliac lymph nodes; 9 peri-pancreatic masses; other sites: mediastinum 12, gastric 25, liver 27, oesophagus 17, duodenum/colon/rectum 15, retro-peritoneum 8, lung 7, miscellaneous 4). RESULTS: The cytology diagnoses were classified as non-neoplastic/reactive in 82 (33%), atypical/suspicious for malignancy in 25 (10%), malignant in 86 (35%) and non-diagnostic in 53 (22%) cases. Surgical pathology follow-up was available in 75 (31%) cases. Excluding the non-diagnostic cases there were 7 false negative and 3 false positive cases. The sensitivity, specificity and positive predictive value of EUS-FNA in the diagnosis of lesions of non-pancreatic sites was 92%, 98% and 97%, respectively. CONCLUSIONS: EUS-FNA can be effectively used as a diagnostic modality in the diagnosis of lesions from non-pancreatic sites.
Authors: David C Chhieng; Darshana Jhala; Nirag Jhala; Isam Eltoum; Victor K Chen; Selwyn Vickers; Martin J Heslin; C Mel Wilcox; Mohamad A Eloubeidi Journal: Cancer Date: 2002-08-25 Impact factor: 6.860
Authors: A Fritscher-Ravens; P V Sriram; C Bobrowski; A Pforte; T Topalidis; C Krause; S Jaeckle; F Thonke; N Soehendra Journal: Am J Gastroenterol Date: 2000-09 Impact factor: 10.864
Authors: Nirag C Jhala; Darshana N Jhala; David C Chhieng; Mohamad A Eloubeidi; Isam A Eltoum Journal: Am J Clin Pathol Date: 2003-09 Impact factor: 2.493
Authors: David C Chhieng; Oscar Lin; Cesar A Moran; Isam A Eltoum; Nirag C Jhala; Darshana N Jhala; Aylin Simsir Journal: Am J Clin Pathol Date: 2002-09 Impact factor: 2.493
Authors: Craig M Womeldorph; Mark M Zalupski; Stewart M Knoepp; Mohammad Soltani; B Joseph Elmunzer Journal: World J Gastrointest Oncol Date: 2010-12-15
Authors: Mohammad S Mahmud; Gray R May; Mohammad M Kamal; Ahmed S Khwaja; Carry Sun; Alex Vitkin; Victor Xd Yang Journal: World J Gastrointest Endosc Date: 2013-11-16
Authors: Christian Jenssen; Maria Victoria Alvarez-Sánchez; Bertrand Napoléon; Siegbert Faiss Journal: World J Gastroenterol Date: 2012-09-14 Impact factor: 5.742